US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sandoz Group AG

44.92

+0.01000.02%

Volume:15.90K

Turnover:718.83K

Market Cap:19.36B

PE:-2.41K

High:45.64

Open:44.68

Low:44.68

Close:44.91

Loading ...

Overview Company News Filings

Sandoz Q1 Revenue Rises 3% To $2.48B, Boosted By Volume Growth Despite Pricing Pressure; For 2025, Expects Mid-Single-Digit Sales Growth And ~21% Core EBITDA Margin

Sandoz announces collaboration license agreement with Henlius

Americans are dangerously dependent on foreign-made generic drugs. Tariffs can fix that.

Sandoz shareholders approve all resolutions at Annual General Meeting

America's generic-drug crisis can be fixed in two words: pharma tariffs

Sandoz files antitrust litigation against Amgen regarding Enbrel

Sandoz price target lowered to CHF 46.50 from CHF 50 at Barclays

Sandoz Group AG Reported FY24 Net Sales Of $10.36B Vs $10.41B Est, Adj EPS Of $2.71

Sandoz launches Pyzchiva in the U.S.

Sandoz downgraded to Neutral from Buy at UBS

Sandoz price target raised to CHF 41 from CHF 39 at Berenberg

SDZNY or ZTS: Which Is the Better Value Stock Right Now?

FDA adds boxed warning to Teva’s Copaxone for allergic reaction

Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer

ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz

Intra-Cellular Therapies Stock Soars 19% After Securing Major Patent Victory Over Sandoz

RBC buyers of Intra-Cellular after ‘more favorable-than-expected’ settlement

SDZNY vs. ZTS: Which Stock Is the Better Value Option?

SDZNY or ZTS: Which Is the Better Value Stock Right Now?

Sandoz enters $275M settlement for antitrust litigation

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SDZNY/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SDZNY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SDZNY\",,,,,undefined,":{"symbol":"SDZNY","market":"US","secType":"STK","nameCN":"Sandoz Group AG","latestPrice":44.92,"timestamp":1747252800000,"preClose":44.91,"halted":0,"volume":15899,"delay":15,"floatShares":399980000,"shares":431000000,"eps":-0.018602,"marketStatus":"Not Yet Opened","change":0.01,"latestTime":"05-14 16:00:00 EDT Delay","open":44.68,"high":45.635,"low":44.68,"amount":718828.5701999997,"amplitude":0.021265,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.018602,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747296000000},"marketStatusCode":0,"adr":0,"adrRate":1,"exchange":"OTCQX","adjPreClose":44.91,"volumeRatio":0.372427},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SDZNY\",,,,,undefined,":{"symbol":"SDZNY","floatShares":399980000,"roa":"0.98%","roe":"0.01%","lyrEps":0.179111,"volumeRatio":0.372427,"shares":431000000,"dividePrice":0.66212,"high":45.635,"amplitude":0.021265,"preClose":44.91,"low":44.68,"week52Low":34.5,"pbRate":"2.37","psRate":"1.86","week52High":49.8099,"institutionHeld":0,"latestPrice":44.92,"eps":-0.018602,"divideRate":0.01474,"volume":15899,"delay":15,"ttmEps":-0.018602,"open":44.68,"prevYearClose":40.5,"prevWeekClose":45.66,"prevMonthClose":43.38,"prevQuarterClose":41.92,"fiveDayClose":44.36,"twentyDayClose":40.52,"sixtyDayClose":46.71},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SDZNY\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531077415","title":"Sandoz Q1 Revenue Rises 3% To $2.48B, Boosted By Volume Growth Despite Pricing Pressure; For 2025, Expects Mid-Single-Digit Sales Growth And ~21% Core EBITDA Margin","url":"https://stock-news.laohu8.com/highlight/detail?id=2531077415","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531077415?lang=en_us&edition=fundamental","pubTime":"2025-04-30 14:26","pubTimestamp":1745994363,"startTime":"0","endTime":"0","summary":"Sandoz Q1 Revenue Rises 3% To $2.48B, Boosted By Volume Growth Despite Pricing Pressure; For 2025, Expects Mid-Single-Digit Sales Growth And ~21% Core EBITDA Margin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/04/45091506/sandoz-q1-revenue-rises-3-to-2-48b-boosted-by-volume-growth-despite-pricing-pressure-for-2025-expec","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SDZNY"],"gpt_icon":0},{"id":"2531752908","title":"Sandoz announces collaboration license agreement with Henlius","url":"https://stock-news.laohu8.com/highlight/detail?id=2531752908","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531752908?lang=en_us&edition=fundamental","pubTime":"2025-04-29 23:10","pubTimestamp":1745939414,"startTime":"0","endTime":"0","summary":"Sandoz (SDZNY) announced that it has signed a global collaboration agreement with Shanghai Henlius Biotech to commercialize a biosimilar of oncolog...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sandoz-announces-collaboration-license-agreement-with-henlius?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sandoz-announces-collaboration-license-agreement-with-henlius?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SDZNY","BK4007"],"gpt_icon":0},{"id":"2527447172","title":"Americans are dangerously dependent on foreign-made generic drugs. Tariffs can fix that.","url":"https://stock-news.laohu8.com/highlight/detail?id=2527447172","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527447172?lang=en_us&edition=fundamental","pubTime":"2025-04-16 00:15","pubTimestamp":1744733700,"startTime":"0","endTime":"0","summary":"Tariffs on pharmaceutical companies isn't just good economic policy - it benefits national security and public health. More than 90% of U.S. prescriptions are for generic drugs, yet more than 80% of the raw materials crucial for drug production are sourced overseas, led by India and China.The United States is facing a dangerous and escalating national security-level health crisis: Americans' overwhelming dependence on foreign-made pharmaceuticals has directly exacerbated the U.S. drug-shortage crisis.Decades of poorly conceived trade policy, offshoring and regulatory neglect have left America critically exposed. More than 90% of U.S. prescriptions are for generic drugs, yet more than 80% of active pharmaceutical ingredients  - the raw materials crucial for drug production - are sourced overseas, led by India and China. Both of these countries aggressively subsidize their domestic pharmaceutical sectors.This economic and regulatory imbalance has hollowed out America's drug manufacturing","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPA","SDZNY","BK4007","BK4500","BK4008"],"gpt_icon":0},{"id":"2527249012","title":"Sandoz shareholders approve all resolutions at Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2527249012","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527249012?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:55","pubTimestamp":1744718110,"startTime":"0","endTime":"0","summary":"Sandoz (SDZNY) announced that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting, including the Annual...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sandoz-shareholders-approve-all-resolutions-at-annual-general-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sandoz-shareholders-approve-all-resolutions-at-annual-general-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SDZNY"],"gpt_icon":0},{"id":"2527533221","title":"America's generic-drug crisis can be fixed in two words: pharma tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2527533221","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527533221?lang=en_us&edition=fundamental","pubTime":"2025-04-14 19:13","pubTimestamp":1744629180,"startTime":"0","endTime":"0","summary":"Strong U.S. production isn't just good economic policy - it's about national security and public health. More than 90% of U.S. prescriptions are for generic drugs, yet more than 80% of the raw materials crucial for drug production are sourced overseas, led by India and China.The United States is facing a dangerous and escalating national security-level health crisis: Americans' overwhelming dependence on foreign-made pharmaceuticals has directly exacerbated the U.S. drug-shortage crisis.From antibiotics and blood-pressure medications to essential cancer treatments, almost all generic drugs consumed in the U.S. are manufactured overseas - primarily in China and India. This dependency jeopardizes patient safety, undermines American health security and weakens the U.S. economy.Decades of poorly conceived trade policy, offshoring and regulatory neglect have left America critically exposed. More than 90% of U.S. prescriptions are for generic drugs, yet more than 80% of active pharmaceutical","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4008","CPA","SDZNY","BK4500"],"gpt_icon":0},{"id":"2527618241","title":"Sandoz files antitrust litigation against Amgen regarding Enbrel","url":"https://stock-news.laohu8.com/highlight/detail?id=2527618241","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527618241?lang=en_us&edition=fundamental","pubTime":"2025-04-14 17:20","pubTimestamp":1744622438,"startTime":"0","endTime":"0","summary":"Sandoz (SDZNY) announced the filing of an antitrust lawsuit in the U.S. against Amgen (AMGN), for extending and entrenching the dominant market pos...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sandoz-files-antitrust-litigation-against-amgen-regarding-enbrel?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sandoz-files-antitrust-litigation-against-amgen-regarding-enbrel?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1023059063.AUD","IE00B4R5TH58.HKD","LU2242652126.USD","BK4599","IE00B2B36J28.USD","BK4139","LU1061106388.HKD","IE0009355771.USD","LU0868494617.USD","LU2468319806.SGD","BK4581","BK4585","BK4588","IE0002141913.USD","BK4533","LU1983299246.USD","LU1571399168.USD","LU1057294990.SGD","LU0122379950.USD","AMGN","BK4534","LU0889565916.HKD","SDZNY","LU0320765992.SGD","LU2112291526.USD","LU0109394709.USD","IE00BJT1NW94.SGD","LU0058720904.USD","IE00BFTCPJ56.SGD","LU0289739699.SGD","BK4007","LU2089984988.USD","IE00BJJMRZ35.SGD","SG9999001440.SGD","LU2242646821.SGD","BK4566"],"gpt_icon":0},{"id":"2524446524","title":"Sandoz price target lowered to CHF 46.50 from CHF 50 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2524446524","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524446524?lang=en_us&edition=fundamental","pubTime":"2025-04-03 03:56","pubTimestamp":1743623772,"startTime":"0","endTime":"0","summary":"Barclays lowered the firm’s price target on Sandoz (SDZNY) to CHF 46.50 from CHF 50 and keeps an Overweight rating on the shares. Published first o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sandoz-price-target-lowered-to-chf-46-50-from-chf-50-at-barclays?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sandoz-price-target-lowered-to-chf-46-50-from-chf-50-at-barclays?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SDZNY"],"gpt_icon":0},{"id":"2517557964","title":"Sandoz Group AG Reported FY24 Net Sales Of $10.36B Vs $10.41B Est, Adj EPS Of $2.71","url":"https://stock-news.laohu8.com/highlight/detail?id=2517557964","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517557964?lang=en_us&edition=fundamental","pubTime":"2025-03-05 15:52","pubTimestamp":1741161145,"startTime":"0","endTime":"0","summary":"Sandoz Group AG Reported FY24 Net Sales Of $10.36B Vs $10.41B Est, Adj EPS Of $2.71","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44135097/sandoz-group-ag-reported-fy24-net-sales-of-10-36b-vs-10-41b-est-adj-eps-of-2-71","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AG","SDZNY"],"gpt_icon":0},{"id":"2513493557","title":"Sandoz launches Pyzchiva in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2513493557","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513493557?lang=en_us&edition=fundamental","pubTime":"2025-02-24 18:28","pubTimestamp":1740392882,"startTime":"0","endTime":"0","summary":"Sandoz (SDZNY) announced the launch of Pyzchiva in the U.S. The medicine is now commercially available to patients across the U.S. Published first ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sandoz-launches-pyzchiva-in-the-u-s?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sandoz-launches-pyzchiva-in-the-u-s?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SDZNY"],"gpt_icon":0},{"id":"2508190207","title":"Sandoz downgraded to Neutral from Buy at UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2508190207","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508190207?lang=en_us&edition=fundamental","pubTime":"2025-02-03 16:55","pubTimestamp":1738572903,"startTime":"0","endTime":"0","summary":"UBS analyst Harry Sephton downgraded Sandoz (SDZNY) to Neutral from Buy with a price target of CHF 44, up from CHF 39.50. The firm cites valuation ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sandoz-downgraded-to-neutral-from-buy-at-ubs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sandoz-downgraded-to-neutral-from-buy-at-ubs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SDZNY","BK4007"],"gpt_icon":0},{"id":"2507586670","title":"Sandoz price target raised to CHF 41 from CHF 39 at Berenberg","url":"https://stock-news.laohu8.com/highlight/detail?id=2507586670","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507586670?lang=en_us&edition=fundamental","pubTime":"2025-01-31 03:45","pubTimestamp":1738266358,"startTime":"0","endTime":"0","summary":"Berenberg raised the firm’s price target on Sandoz (SDZNY) to CHF 41 from CHF 39 and keeps a Hold rating on the shares. Published first on TheFly –...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sandoz-price-target-raised-to-chf-41-from-chf-39-at-berenberg?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sandoz-price-target-raised-to-chf-41-from-chf-39-at-berenberg?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SDZNY"],"gpt_icon":0},{"id":"2505710297","title":"SDZNY or ZTS: Which Is the Better Value Stock Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2505710297","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505710297?lang=en_us&edition=fundamental","pubTime":"2025-01-23 00:40","pubTimestamp":1737564015,"startTime":"0","endTime":"0","summary":"Investors interested in stocks from the Medical - Drugs sector have probably already heard of Sandoz Group AG Sponsored ADR  and Zoetis . But which of these two stocks presents investors with the better value opportunity right now?We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.Right now, Sandoz Group AG Sponsored ADR is sporting a Zacks Rank of #2 , while Zoetis has a Zacks Rank of #3 . Investors should feel comfortable knowing that SDZNY likely has seen a stronger improvement to its earnings outlook than ZTS has recently. However, value investors will care about much more than just this.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sdzny-zts-better-value-stock-164015605.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2028103732.USD","LU1941712264.USD","LU0058720904.USD","BK4588","BK4585","LU2111349929.HKD","BK4534","LU0471298777.SGD","LU0158827781.USD","LU0385154629.USD","LU0345774631.USD","LU1941712348.USD","LU2089283258.USD","ZTS","LU0471298694.HKD","LU0158827948.USD","LU2360106947.USD","LU2089284900.SGD","LU2023251221.USD","SDZNY","LU0289739699.SGD","LU0079474960.USD","IE00B19Z9505.USD","LU2308191902.HKD","BK4007","LU2271345857.HKD","LU0345774391.USD"],"gpt_icon":0},{"id":"2505013778","title":"FDA adds boxed warning to Teva’s Copaxone for allergic reaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2505013778","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505013778?lang=en_us&edition=fundamental","pubTime":"2025-01-23 00:25","pubTimestamp":1737563135,"startTime":"0","endTime":"0","summary":"The Food and Drug Administration is adding a boxed warning about the risk of an allergic reaction for Teva‘s (TEVA) Copaxone and Sandoz’s (SDZNY) G...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-adds-boxed-warning-to-tevas-copaxone-for-allergic-reaction?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-adds-boxed-warning-to-tevas-copaxone-for-allergic-reaction?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","TEVA","BK4557","BK4559","BK4007","SDZNY","BK4566","BK4584","BK4588","BK4596"],"gpt_icon":0},{"id":"2503653570","title":"Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2503653570","media":"Zacks","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503653570?lang=en_us&edition=fundamental","pubTime":"2025-01-14 21:54","pubTimestamp":1736862840,"startTime":"0","endTime":"0","summary":"Intra-Cellular Therapies ITCI signed a definitive agreement with pharma bigwig Johnson & Johnson JNJ. Per the terms, the pharma giant will acquire all outstanding shares of ITCI for $132 per share in cash, aggregating to nearly $14.6 billion.A commercial-stage biotech company, Intra-Cellular is focused on developing and marketing novel drugs targeting neuropsychiatric and neurological disorders.The acquisition will add ITCI’s sole marketed drug, Caplyta, which is approved for two indications — schizophrenia and bipolar depression. A regulatory filing was submitted to the FDA last month seeking label expansion for this oral therapy in the major depressive disorder  indication.ITCI is also developing its pipeline candidate ITI-1284 for multiple indications — generalized anxiety disorder, and Alzheimer's disease-related psychosis and agitation — across several mid-stage programs. Post the acquisition, J&J will add this investigational drug to its pipeline.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/intra-cellular-therapies-stock-34-135400738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","IE00B1BXHZ80.USD","LU1894683264.USD","LU1674673428.USD","LU0889565916.HKD","LU1032466523.USD","BK4007","BK4533","LU0109394709.USD","LU1162221912.USD","LU1261432733.SGD","LU1032955483.USD","LU1914381329.SGD","IE00B3PB1722.GBP","LU1732800096.USD","SG9999002224.SGD","LU0640476718.USD","LU1066051498.USD","LU1057294990.SGD","LU0289739699.SGD","SDZNY","IE00B2B36J28.USD","LU1066053197.SGD","LU0053671581.USD","LU1059921491.USD","LU1732799900.SGD","LU2089984988.USD","ABVC","IE00BGHQF631.EUR","LU0098860793.USD","LU0889566641.SGD","LU1506573853.SGD","LU0122379950.USD","LU0792757196.USD","LU2602419157.SGD","IE00BJT1NW94.SGD","LU1718418525.SGD","IE00BFTCPJ56.SGD","JNJ","BK4581","IE00B19Z3B42.SGD","LU0058720904.USD","LU0795875169.SGD","LU1221951129.SGD","LU0882574055.USD","LU0320765646.SGD","LU0012050646.USD","LU0912757837.SGD","ITCI","IE00BVYPNV92.GBP"],"gpt_icon":0},{"id":"2503534916","title":"ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz","url":"https://stock-news.laohu8.com/highlight/detail?id=2503534916","media":"Zacks","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503534916?lang=en_us&edition=fundamental","pubTime":"2025-01-14 00:40","pubTimestamp":1736786400,"startTime":"0","endTime":"0","summary":"Shares of Intra-Cellular Therapies ITCI rallied 14.9% on Friday after the company announced that it has entered into a settlement agreement with Sandoz SDZNY regarding the Caplyta  patent litigation.The settlement agreement resolves the patent litigation brought by Intra-Cellular on Sandoz for submitting an abbreviated new drug application to the FDA seeking marketing approval for a generic version ofCaplyta in the United States before applicable patents expire. The litigation is currently pending in the U.S. District Court in New Jersey.Caplyta is approved in the United States for the treatment of schizophrenia in adults. Later, its indication was expanded to treat bipolar depression in adults. Intra-Cellular’s Caplyta is currently the only approved treatment, both as monotherapy and as adjunctive therapy with lithium or valproate, for depressive episodes associated with bipolar depression in adults.In 2022, the FDA approved two new dosage strengths of Caplyta, 10.5 mg and 21 mg for p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/itci-stock-rises-15-settling-164000815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","LU0109394709.USD","LU0053671581.USD","SDZNY","BK4196","LU0320765992.SGD","LU0012050646.USD","LU0106261612.USD","LU0889565916.HKD","BK4139","CSTL","CTMX","ITCI"],"gpt_icon":0},{"id":"2502815786","title":"Intra-Cellular Therapies Stock Soars 19% After Securing Major Patent Victory Over Sandoz","url":"https://stock-news.laohu8.com/highlight/detail?id=2502815786","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502815786?lang=en_us&edition=fundamental","pubTime":"2025-01-11 02:11","pubTimestamp":1736532713,"startTime":"0","endTime":"0","summary":"Intra-Cellular Therapies  just had a day for the books. Its stock shot up 19%, smashing records, after the company locked in a game-changing patent settlement with Sandoz . The deal resolves a lawsuit over CAPLYTA , Intra-Cellular's go-to bipolar depression treatment. Here's the kicker: Sandoz can't launch a generic version until July 1, 2040unless some unusual circumstances fast-track it. That's 16 more years of market exclusivity for CAPLYTA, which is a huge win for Intra-Cellular. The agreement is already headed to U.S. regulators for review, while similar lawsuits with other parties are still grinding through New Jersey's federal courts.This settlement isn't just a legal win; it's a statement. Intra-Cellular now has an extended window to maximize CAPLYTA's earning potential, and investors are betting big that this move secures its leadership in CNS therapeutics. The stock's meteoric rise tells the whole story: this company is on a roll, and it's not slowing down anytime soon.This a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/intra-cellular-therapies-stock-soars-181153766.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","LU0053671581.USD","SDZNY","ITCI","LU0106261612.USD","BK4007","LU0012050646.USD"],"gpt_icon":0},{"id":"2502895156","title":"RBC buyers of Intra-Cellular after ‘more favorable-than-expected’ settlement","url":"https://stock-news.laohu8.com/highlight/detail?id=2502895156","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502895156?lang=en_us&edition=fundamental","pubTime":"2025-01-10 23:40","pubTimestamp":1736523617,"startTime":"0","endTime":"0","summary":"After Intra-Cellular Therapies (ITCI) announced that it has entered into a settlement agreement with Sandoz (SDZNY) resolving patent litigation rel...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rbc-buyers-of-intra-cellular-after-more-favorable-than-expected-settlement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rbc-buyers-of-intra-cellular-after-more-favorable-than-expected-settlement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","LU0053671581.USD","SDZNY","LU0889565916.HKD","BK4007","LU0106261612.USD","LU0012050646.USD","ITCI","LU0109394709.USD"],"gpt_icon":0},{"id":"2501826426","title":"SDZNY vs. ZTS: Which Stock Is the Better Value Option?","url":"https://stock-news.laohu8.com/highlight/detail?id=2501826426","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501826426?lang=en_us&edition=fundamental","pubTime":"2025-01-07 00:40","pubTimestamp":1736181609,"startTime":"0","endTime":"0","summary":"Investors interested in Medical - Drugs stocks are likely familiar with Sandoz Group AG Sponsored ADR  and Zoetis . But which of these two stocks offers value investors a better bang for their buck right now?The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.Right now, Sandoz Group AG Sponsored ADR is sporting a Zacks Rank of #2 , while Zoetis has a Zacks Rank of #3 . This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that SDZNY is likely seeing its earnings outlook improve to a greater extent. But this is just one piece of the puzzle for value investors.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sdzny-vs-zts-stock-better-164009594.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2023251221.USD","LU2271345857.HKD","LU0058720904.USD","BK4585","LU0345774631.USD","LU2028103732.USD","LU0079474960.USD","LU2089283258.USD","LU2089284900.SGD","LU0289739699.SGD","BK4588","LU2360106947.USD","LU0385154629.USD","BK4007","LU1941712348.USD","LU0471298777.SGD","LU1941712264.USD","ZTS","LU0471298694.HKD","IE00B19Z9505.USD","LU0158827948.USD","SDZNY","LU2111349929.HKD","BK4534","LU2308191902.HKD","LU0158827781.USD","LU0345774391.USD"],"gpt_icon":0},{"id":"2493742010","title":"SDZNY or ZTS: Which Is the Better Value Stock Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2493742010","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493742010?lang=en_us&edition=fundamental","pubTime":"2024-12-21 00:40","pubTimestamp":1734712811,"startTime":"0","endTime":"0","summary":"Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR  or Zoetis . But which of these two stocks offers value investors a better bang for their buck right now?Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.Currently, Sandoz Group AG Sponsored ADR has a Zacks Rank of #1 , while Zoetis has a Zacks Rank of #3 . The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that SDZNY has an improving earnings outlook. But this is just one factor that value investors are interested in.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d6hN0_BhikrNdWTnix6fng--~B/aD03NDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d6hN0_BhikrNdWTnix6fng--~B/aD03NDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sdzny-zts-better-value-stock-164011203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1941712264.USD","LU2111349929.HKD","LU2308191902.HKD","BK4588","LU0158827781.USD","LU0079474960.USD","LU0345774391.USD","LU0289739699.SGD","BK4534","LU2271345857.HKD","LU0385154629.USD","IE00B19Z9505.USD","LU2023251221.USD","BK4007","LU1941712348.USD","LU2089284900.SGD","SDZNY","LU0058720904.USD","LU2028103732.USD","LU0345774631.USD","LU2089283258.USD","LU0471298694.HKD","LU0471298777.SGD","BK4585","LU0158827948.USD","ZTS","LU2360106947.USD"],"gpt_icon":0},{"id":"2492934011","title":"Sandoz enters $275M settlement for antitrust litigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2492934011","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492934011?lang=en_us&edition=fundamental","pubTime":"2024-12-17 18:30","pubTimestamp":1734431436,"startTime":"0","endTime":"0","summary":"Sandoz (SDZNY) announced a number of steps to resolve the US Generic Drug Antitrust Class Action Litigation. Following the previously announced set...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sandoz-enters-275m-settlement-for-antitrust-litigation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sandoz-enters-275m-settlement-for-antitrust-litigation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SDZNY"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SDZNY\",params:#limit:5,,,undefined,":[{"date":"2025-04-22","symbol":"SDZNY","amount":0.67446,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-22","defaultRemindTime":1745328600000,"name":"Sandoz Group AG","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-23","payableDate":"2025-04-22","currency":"USD","dateTimestamp":1745294400000,"payDate":"2025-04-23"},{"date":"2024-05-03","symbol":"SDZNY","amount":0.4983609,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-05-06","defaultRemindTime":1714743000000,"name":"Sandoz Group AG","recordDate":"2024-05-07","payableDate":"2024-05-06","currency":"USD","dateTimestamp":1714708800000,"payDate":"2024-05-07"},{"market":"US","date":"2024-03-13","symbol":"SDZNY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1710302400000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SDZNY\",market:\"US\",,,undefined,":[{"executeDate":"2024-05-03","recordDate":"2024-05-06","paymentDate":"2024-05-07","value":0.4983609,"currency":"USD"},{"executeDate":"2025-04-22","recordDate":"2025-04-22","paymentDate":"2025-04-23","value":0.67446,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SDZNY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.5,"hold":0.2143,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":14,"updateTime":1746244800000}}}